Drug profile

The FDA adverse-event record for Lokivetmab Injectable Solution

276 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Lokivetmab Injectable Solution. See the species affected, top reactions, and outcomes below.

276
adverse-event reports
6.9%
death-coded share
Dog
most-reported species
46
Vomiting - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
276
Total Reports
19
Deaths Reported
6.9%
Death Rate

Active Ingredients

Lokivetmab Injectable Solution

Administration Routes

UnknownParenteralSubcutaneousOtherIntramuscular

Species Affected

Dog 275
Cat 1

Most Affected Breeds

Retriever - Labrador 34
Crossbred Canine/dog 17
Shih Tzu 15
Shepherd Dog - German 13
Bulldog - French 13
Terrier - Yorkshire 13
Retriever - Golden 10
Pit Bull 9
Pug 8
Shepherd Dog - Australian 8

Most Reported Reactions

Vomiting 46
Lack of efficacy - NOS 43
Lethargy (see also Central nervous system depression in Neurological) 32
Diarrhoea 25
Elevated serum alkaline phosphatase (ALP) 22
Elevated alanine aminotransferase (ALT) 15
Anorexia 14
Other abnormal test result NOS 14
Not eating 13
Death by euthanasia 13
Decreased appetite 13
Panting 13

Outcome Breakdown

Ongoing
112 (40.6%)
Outcome Unknown
100 (36.2%)
Recovered/Normal
44 (15.9%)
Euthanized
13 (4.7%)
Died
6 (2.2%)
Recovered with Sequela
1 (0.4%)

Lokivetmab Injectable Solution Adverse Event Insights

276 reports name Lokivetmab Injectable Solution; 19 recorded a death outcome (6.9% of reported events, not a population-level mortality rate). Active ingredient: Lokivetmab Injectable Solution. Administration routes: Unknown, Parenteral, Subcutaneous, Other.

By species: Dog (275 reports), Cat (1 reports). By breed: Retriever - Labrador (34), Crossbred Canine/dog (17), Shih Tzu (15).

Leading clinical signs: Vomiting (46), Lack of efficacy - NOS (43), Lethargy (see also Central nervous system depression in Neurological) (32), Diarrhoea (25). Outcome, 276 coded reports: Ongoing leads at 40.6%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.